SUNRIDGE MEDICAL • INTEGRATIVE ONCOLOGY
Green tea and concentrated EGCG extracts are not interchangeable. A physician can review the proposed product, dose, liver status, medications and oncology treatment.
Share your diagnosis, treatment and the exact green-tea or EGCG product you are considering.
EGCG and cancer research has attracted sustained scientific interest because epigallocatechin-3-gallate can influence multiple pathways involved in cell growth, apoptosis, inflammation, angiogenesis and cancer-cell signaling.
Epigallocatechin-3-gallate (EGCG) is the best-known catechin in green tea. The National Cancer Institute identifies EGCG as a substance found in green tea that is being studied in cancer prevention and other diseases.1
At Sunridge Medical, EGCG or standardized green-tea catechin preparations may be considered as part of a physician-directed integrative cancer treatment strategy when appropriate for the individual patient.
The goal is not to treat green tea as a universal cancer protocol. The goal is to understand the compound, the research, the tumor biology, potential drug interactions and how EGCG may fit into a broader individualized oncology program.
Green tea is naturally rich in catechins, including epigallocatechin-3-gallate (EGCG).
GREEN TEA POLYPHENOL • ONCOLOGY RESEARCH
EGCG stands for epigallocatechin-3-gallate. It is one of the principal polyphenols found in green tea produced from Camellia sinensis.
NCI describes green tea as containing several catechins, with EGCG representing a major component of its polyphenol fraction.2
EGCG has attracted cancer-research interest because it can interact with a wide range of molecular targets. Depending upon the experimental model, investigators have reported effects involving proliferation, apoptosis, growth-factor signaling, angiogenesis, inflammatory pathways and gene regulation.
COMPOUND VS BOTANICAL EXTRACT
It is important to distinguish between green tea, green tea extract and purified or standardized EGCG.
Clinical research involving standardized extracts should not automatically be interpreted as evidence that drinking an ordinary amount of tea produces the same pharmacologic exposure.
EGCG has been investigated for effects on multiple cancer-related signaling pathways.
MULTI-TARGETED BIOLOGY
Unlike a drug designed around a single molecular target, EGCG has demonstrated activity across numerous biochemical pathways in laboratory research.
This helps explain why EGCG and cancer appears across studies involving many different tumor types.
Researchers have examined potential effects involving:
The biological breadth is scientifically interesting, but laboratory activity does not automatically translate into a clinical cancer treatment. Human studies remain essential.
CELL GROWTH & SIGNALING
One recurring area of laboratory research is EGCG’s ability to alter signaling pathways that cancer cells use for growth and survival.
For example, experimental breast-cancer research found that EGCG inhibited HER2/neu signaling, proliferation and transformed cellular behavior.3
Other laboratory work has shown effects on Wnt signaling in invasive breast-cancer cells through regulation of the HBP1 transcriptional repressor.4
These studies help establish biological plausibility for EGCG as a multi-target compound, while also emphasizing that the effects were demonstrated in experimental systems rather than as proven clinical treatment outcomes.
PROGRAMMED CELL DEATH
Apoptosis is the controlled process through which damaged or abnormal cells can be eliminated.
Many cancer cells develop mechanisms that allow them to resist normal apoptosis signals. EGCG has therefore been studied for its ability to influence cell-death pathways and the balance between pro-survival and pro-apoptotic signaling.
Research across multiple tumor models has reported changes in caspase activity, mitochondrial signaling and survival pathways after EGCG exposure. These findings are one reason EGCG continues to be investigated as part of cancer-prevention and treatment research.
TUMOR MICROENVIRONMENT
For a tumor to expand, it must interact with surrounding tissue, recruit blood vessels and, in advanced disease, develop the ability to invade and migrate.
EGCG has been studied for potential effects on angiogenesis, epithelial-mesenchymal transition, migration and invasion. In lung-cancer cell research, EGCG inhibited nicotine-associated angiogenic and invasive signaling in A549 cells.5
These are preclinical findings, but they contribute to the broader picture of EGCG as a compound capable of influencing more than one component of tumor biology.
HUMAN CLINICAL RESEARCH
Human research is especially important because concentrations that alter cancer cells in a laboratory dish may not be achievable or behave the same way inside the human body.
Clinical studies of green-tea extracts and standardized catechin preparations have examined early-stage leukemia, solid tumors, breast cancer, prostate-cancer risk and oral premalignant lesions.
The results are mixed. Some trials have shown measurable biologic activity, while others have not demonstrated a significant reduction in cancer incidence or objective tumor response.
PHASE II HUMAN STUDY
One of the more frequently cited human studies of EGCG involved patients with asymptomatic, early-stage chronic lymphocytic leukemia (CLL).
In a phase II trial, 42 previously untreated patients received the standardized green-tea catechin preparation Polyphenon E for up to six months.6
The investigators reported durable reductions in absolute lymphocyte count and/or lymph-node size in many participants. The study demonstrated biologic activity in early-stage CLL, but it was not designed to establish EGCG as a replacement for modern leukemia treatment or to prove a survival benefit.
This study is important because it shows that EGCG and cancer research has produced measurable human biologic signals rather than existing only in cell-culture experiments.
PHASE I SOLID-TUMOR STUDY
An earlier phase I study evaluated oral green-tea extract in 49 adults with cancer, including patients with non-small-cell lung cancer, head and neck cancer, mesothelioma and other solid tumors.7
No major tumor responses were observed. Ten patients with stable disease were able to complete six months of treatment. The main dose-limiting effects of the preparation were related to caffeine.
The trial was primarily a safety and pharmacology study. Its value is in showing what happened when concentrated green-tea extract was formally studied in a population with advanced cancer rather than extrapolating from laboratory research.
RANDOMIZED PHASE II TRIAL
A randomized phase II study evaluated green-tea extract in patients with high-risk oral premalignant lesions.8
The combined green-tea extract groups had a clinical response rate of 50% compared with 18.2% for placebo, although the difference did not reach conventional statistical significance in this relatively small trial.
The study also investigated tissue biomarkers and dose-response relationships, adding to evidence that standardized green-tea preparations can produce measurable biologic effects in human tissues.
PROSTATE-CANCER PREVENTION RESEARCH
Green-tea catechins have also been studied in men with high-grade prostatic intraepithelial neoplasia or atypical small acinar proliferation.
In a randomized placebo-controlled trial involving 97 men, a standardized decaffeinated catechin mixture containing EGCG was taken for one year.9
The trial did not show a statistically significant reduction in the overall number of prostate-cancer diagnoses between the treatment and placebo groups, although some secondary endpoints favored the catechin group.
NCI’s prostate-cancer supplement review likewise concludes that current evidence is insufficient to establish green tea as a treatment or preventive therapy for prostate cancer.10
BREAST-CANCER RESEARCH
A phase IB randomized, double-blinded, placebo-controlled dose-escalation study evaluated Polyphenon E in women with hormone receptor-negative breast cancer.11
This type of study is designed primarily to evaluate tolerability, pharmacokinetics and biological effects rather than prove that a treatment improves cancer outcomes.
Subsequent analyses examined changes in systemic growth-factor and signaling biomarkers in participants receiving the green-tea extract.12
These studies add to the human research base while also illustrating the gap between promising molecular activity and definitive evidence of clinical benefit.
TREATMENT COORDINATION
Because EGCG is pharmacologically active, its interactions with cancer therapies deserve the same attention given to drug-drug interactions.
NCI’s review of cancer-therapy interactions notes that green tea and EGCG can affect the pharmacokinetics or pharmacodynamics of some anticancer agents.13
The best-known example involves bortezomib. Preclinical studies found that EGCG could bind to the boronic-acid structure of bortezomib and interfere with its anticancer activity.14
NCI also summarizes preclinical or case-based interaction concerns involving drugs such as sunitinib, palbociclib, erlotinib, lapatinib, irinotecan and fluorouracil.13
This is one reason EGCG should be incorporated through a physician-directed oncology plan rather than simply added to an existing regimen without reviewing the medications being used.
PHYSICIAN-DIRECTED MONITORING
Green tea as a beverage and concentrated green-tea extracts are not pharmacologically equivalent.
NCI notes that rare cases of liver injury have occurred with green-tea extracts taken in pill form.15 Clinical trials of concentrated catechin preparations have therefore used laboratory monitoring and defined eligibility criteria.
For a patient with cancer, liver function may already be influenced by metastatic disease, chemotherapy, targeted therapy, immunotherapy or other medications. That makes the patient’s overall treatment context especially important when considering concentrated EGCG.
SUNRIDGE MEDICAL
At Sunridge Medical, the discussion around EGCG and cancer is not limited to whether a laboratory study showed activity against a tumor cell line.
We consider the broader clinical picture, which may include:
When appropriate, EGCG may be incorporated as one part of a broader program involving physician-directed nutritional medicine, botanical medicine, IV therapies, metabolic strategies and other integrative approaches.
WHERE THE RESEARCH IS HEADING
EGCG sits at the intersection of botanical medicine, nutrition science and molecular oncology.
It is a naturally occurring green-tea catechin, yet it has been investigated in formal phase I and phase II human trials. Laboratory research suggests multi-pathway activity, while human trials show that standardized catechin preparations can alter some biological endpoints.
At the same time, EGCG and cancer research has not established EGCG as a universal anticancer therapy. Outcomes differ across diseases and study designs, and formulation, dose, bioavailability and treatment interactions all matter.
That combination of intriguing biology and incomplete clinical evidence is precisely why careful physician-directed use and continued research are important.
FREQUENTLY ASKED QUESTIONS
EGCG, or epigallocatechin-3-gallate, is a catechin found naturally in green tea. It is one of the most extensively studied green-tea polyphenols.
Experimental studies have reported effects involving cell proliferation, apoptosis, growth-factor signaling, angiogenesis, invasion, inflammation and gene regulation.
Yes. Standardized green-tea catechin preparations have been evaluated in human studies involving early-stage CLL, solid tumors, hormone receptor-negative breast cancer, prostate-cancer risk and oral premalignant lesions.
Human studies have demonstrated biological activity in some settings, but EGCG has not been established as a stand-alone treatment for cancer or as a substitute for evidence-based oncology treatment.
Polyphenon E is a standardized green-tea catechin preparation used in multiple clinical studies. It contains EGCG along with other catechins.
Yes. NCI reviews potential interactions between green tea or EGCG and several anticancer drugs. The bortezomib interaction is particularly important because preclinical work found that EGCG could antagonize its anticancer effect.
Rare liver injury has been reported with concentrated green-tea extracts in pill form, which is one reason physician-directed monitoring can be important.
EGCG or standardized green-tea catechin preparations may be considered within an individualized integrative oncology program when clinically appropriate.
BECOME A PATIENT
EGCG is one of many natural compounds being investigated for its effects on cancer biology. At Sunridge Medical, these therapies are evaluated within the context of the individual patient’s diagnosis, medications, laboratory findings and broader oncology treatment.
Speak with our Patient Care Team about your diagnosis, previous treatment and current goals.
RESEARCH
Browse 27 source-linked studies with the full title, publication year, research focus and a concise finding. Select any linked cancer type to move directly to its corresponding Sunridge page.
In this study, we designed and characterized a novel self-assembled nanomedicine by mixing ferrous ions (Fe2+) and epigallocatechin gallate (EGCG) in a controllable manner and encapsulating the ferroptosis inducer RSL3, named Fe-EGCG@RSL3.
Here, cellular experiments showed that EGCG significantly promoted OS cell apoptosis and inhibited proliferation, migration and invasion, and cell and animal experiments demonstrated that the Wnt/β-catenin pathway played an indispensable role in the antitumour effects of EGCG.
Our triple-drug combination therapy significantly inhibited tumor growth in vivo and increased the survival rate (50%) of rats when compared with individual or dual treatments.
EGCG inhibited cell proliferation with IC50 values of 127.8 μM (U87), 172.9 μM (U251), and 104.7 μM (LN229) in glioma cells, while inducing apoptosis.
Based on this lacuna, the current study aimed to explore the therapeutic efficacy of the triple-drug combination of temozolomide, metformin and epigallocatechin gallate in attenuating Warburg effect and glucose uptake in glioblastoma both in vitro and in vivo.
EGCG treatment under TGF-β, reduced PD-L1, CD55 and CD46 expression, decreased viability, metabolic activity and MMP-2 secretion, while inducing apoptosis in SiHa co-culture.
Because it has chemopreventive and anti-invasive effect against various cancer cells, EGCG can be used to inhibit proliferation and invasion of cholangiocarcinoma (CCA) cells.
EGCG induced apoptosis and significantly suppressed the proliferation of colon cancer cells, both in vitro and in vivo.
At week 12, high-dose EGCG treatment significantly reduced the tumor formation rate, total number of tumors, cancerous and non-cancerous tumors, tumor volume, ascites formation, and aberrant crypt foci count.
In this study, we observed the antitumor activity following combinatorial therapy with anti-CTLA4 antibody and epigallocatechin-3-gallate (EGCG) in CT26 tumors.Indeed, EGCG triggered colon cancer cells ICD with the secretion of high-mobility group protein B1 (HMGB1) and the surface expression of calreticulin (CRT) and heat shock protein 70 (HSP70).
The study underscores the potential of nanoparticles in enhancing EGCG delivery for colorectal cancer therapy, aiming to minimize side effects and improve therapeutic outcomes.
Anti-cancer properties of (-)-epigallocatechin-3-gallate (EGCG) are mediated via apoptosis induction, as well as inhibition of cell proliferation and histone deacetylase.
EGCG derived from HDI inhibits GC cell proliferation and targets STAT3 to inhibit M2 polarization induced by PLXNC1-mediated exosomes derived from GC cells, which may be a multi-target therapeutic agent for GC cell proliferation and immune microenvironment.
Herein, the study showed that EGCG could significantly inhibit cell proliferation and promote apoptosis of 2 NPC (CNE-2 and 5-8F) cell lines.
The DiOC6 (3) negative cell rate was increased and p65 of NF-κB, XIAP and survivin expression was reduced by the combination treatment.In summary, EGCG sensitizes NPC cells to TRAIL-mediated apoptosis via modulation of extrinsic and intrinsic apoptotic pathways and inhibition of NF-κB activation.
The results revealed that EGCG considerably inhibited the migration abilities of three NPC cells.
Moreover, EGCG showed inhibition of ROS production in NB4 cells in the presence of N-acetyl-L-cysteine (NAC), as well as a partial blockage of neutrophil differentiation and apoptosis, indicating that EGCG-activities involve/or are in response of oxidative stress.
Epigallocatechin gallate (EGCG), a bioactive polyphenol from green tea, has attracted immense interest as a potential chemosensitizer, but its application is limited due to the need for effective formulations capable of co-delivering EGCG and anti-leukemic drugs.
The study reports sphK1 inhibitor potentiates the anti-cancer effect of EGCG on leukaemia cells.
EGCG significantly reduced cell proliferation and induced apoptosis in all cell lines.
Currently, we found that leptin-triggered M2 polarization of tumor-associated macrophages was inhibited by EGCG.
Therefore, the combination of EGCG with vincristine has a better antineoplastic effect by inhibiting tumor development and increasing survival on both substances independently.
Nano-EGCG formulations had enhanced stability and produced greater suppression of melanoma tumor growth and angiogenesis compared with free EGCG.
When the resulting tumors were analyzed, we found that EGCG decreased tumor-induced HIF-1[Formula: see text] and tumor growth.
The Cu-EQ NPs leverage the tumor microenvironment to release copper ions that trigger TCA-dependent cuproptosis, while the EGCG component simultaneously inhibits key glycolytic enzymes to prevent metabolic escape.
Epigallocatechin gallate (EGCG), a major polyphenol of green tea, has been shown to inhibit cancer cell proliferation.
Here, cellular experiments showed that EGCG significantly promoted OS cell apoptosis and inhibited proliferation, migration and invasion, and cell and animal experiments demonstrated that the Wnt/β-catenin pathway played an indispensable role in the antitumour effects of EGCG.
No studies match those filters. Clear a filter or try a broader term.
14200 N Northsight Blvd #160
Scottsdale, Arizona 85260
Monday–Friday: 9:00 AM–5:00 PM
Saturday: 9:00 AM–12:00 PM
Tell us what you are facing. There is no charge to speak with our Patient Care Team, understand how Sunridge works and determine whether a physician consultation may be an appropriate next step.
This introductory call is not a medical consultation and does not establish a physician-patient relationship.
